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Background: MicroRNAs are endogenous small noncoding RNAs that are functionally involved in numerous critical
cellular processes including tumorigenesis. Data mining using a microRNA array database suggested that let-7d
microRNA may be associated with renal cell carcinoma (RCC) malignant progression. Here, we performed further
analyses to determine whether let-7d is functionally linked to RCC malignancy.
Methods: Quantitative real-time PCR was used to determine the level of mature let-7d in RCC clinical specimens
and its correlation with clinicopathological data. Immunohistochemical staining was conducted to characterize
the stroma of RCC. Let-7d overexpressing RCC cell lines combined with mouse models bearing cell-derived
xenografts and patient-derived xenografts were used to assess the functional role of let-7d in vitro and
in vivo.
Results: Downregulation of let-7d in clinical RCC samples was associated with advanced tumor grade and T stage and
increased vascular invasion. An inverse relationship between let-7d expression and macrophage infiltration was found
in clinical RCC samples. Functional studies indicated that ectopic expression of let-7d significantly inhibited RCC cell
proliferation, migration, and peripheral blood monocyte (PBMC) recruitment in vitro, as well as tumor growth,
metastasis, and tumor macrophage infiltration in vivo. In silico analysis and subsequent experimental validation confirmed
collagen, type III, alpha 1 (COL3A1) and C-C subfamily chemokine member CCL7 as direct let-7d target genes. The
addition of COL3A1 and CCL7 counteracted the inhibitory effects of let-7d on RCC cell proliferation, migration, and
PBMC recruitment. The inhibition of let-7d increased cell proliferation, migration, and PBMC recruitment by the
enhanced expression of COL3A1 and CCL7 genes in vitro. The mRNA levels of COL3A1 and CCL7 were inversely
correlated with let-7d level in RCC clinical specimens.
Conclusions: These results suggest that let-7d may suppress RCC growth, metastasis, and tumor macrophage
infiltration at least partially through targeting COL3A1 and CCL7.
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Renal cell carcinoma (RCC) is one of the common uro-
logical cancers usually with poor prognosis [1]. RCC
accounts for approximately 3% of adult malignancies
and for approximately 90–95% of neoplasms arising from
the kidney [2,3]. Surgical treatment can cure 60–70% of
localized RCC but only prolongs survival in most meta-
static RCC patients [4]. RCC is relatively resistant to radi-
ation and chemotherapy [5]. Considerable progress has
been made in the therapy of patients with localized RCC;
however, the treatment options for patients with meta-
static RCC are very limited [6]. Therefore, identification of
new biomarker and anti-tumor agents, particularly with
better efficiency against metastatic RCC, remains a high
priority.
MicroRNAs (miRNAs) are a large gene family of short
(21–23 nucleotides) non-coding RNAs. The single-stranded
miRNA binds through imperfect base pairing with the 3′
untranslated region (3′-UTR) of target mRNAs and causes
either repression of translation or degradation of mRNAs
[7]. Each of the hundreds of known miRNAs can epigenet-
ically downregulate many target genes that participate in
various biological processes including cell proliferation,
apoptosis, migration, differentiation and development [8].
It is increasingly apparent that the interplay between
cancer cells and their stroma is of great importance to
tumorigenesis and progression [9]. Tumor-associated
stroma is composed of multiple stromal cell types,
such as cancer-associated fibroblasts, immune inflam-
matory cells, and endothelial cells, as well as a variety of
extracellular matrix (ECM) proteins, such as fibronectin
and collagen. The tumor-associated stroma constitutes
an important compartment of tumor microenvironment,
which can enable primary, invasive, and then metastatic
growth of tumor through crosstalk with cancer cells [10].
Recent studies have shown that the regulatory role of
miRNAs during cancer progression is not limited to
cancer cells, and that miRNAs are also involved in the
activation and transition of tumor stromal cells [11].
Thus, miRNAs have emerged as a potent regulator in
the crosstalk between cancer and stromal cells in the
tumor microenvironment.
The let-7 family, originally identified in Caenorhabditis
elegans, consists of 13 family members that are highly
conserved across the animal phylogeny from C. elegans
to human. Nine members of the let-7 family have been
identified in humans [12]. Let-7 functions as a heterochro-
nic gene in many species. It is undetectable in human and
mouse embryonic stem cells, but increases during em-
bryogenesis and differentiation [13]. High let-7 expression
levels are subsequently maintained in a variety of adult
tissues [14]. Conversely, let-7 is frequently downregulated
in many human malignancies, such as lung cancer, breast
cancer, and hepatocellular carcinoma [15-17], possiblyreflecting the reverse embryogenesis process that occurs
during oncogenesis [18].
Recently, we have identified a subset of miRNAs that
are low expressed in RCC relative to adjacent normal tis-
sues by using microarray (unpublished data). The current
study was designed to explore the function of one of these
miRNAs, let-7d, in RCC progression.
Results
Let-7d is downregulated in human RCC cell lines and
clinical RCC samples
We examined let-7d expression in several human RCC
cell lines by quantitative real-time RT-PCR. The normal
renal tubule epithelial cell line HK-2 had significantly
higher let-7d level than the RCC cell lines (Figure 1A).
We then examined let-7d expression in 80 clinical RCC
samples and their matched adjacent tissues. The mean
let-7d level in RCC was 17.6% of that in the matched adja-
cent tissues (Figure 1B). Given that let-7 family members
are sometimes indistinguishable [19], we also checked the
expression of let-7a, the only let-7 family member that
was reported to function as a tumor suppressor in RCC
cell lines [20]. As shown in Additional file 1: Figure S1
(Supplementary Data), no difference of let-7a expression
was found between tumor tissues and the matched ad-
jacent tissues. These data indicate that the decrease of
let-7d expression in RCC may be specific.
Decreased let-7d expression is associated with advanced
T stages and tumor grades in RCC patients
A total of 80 RCC patients were analyzed for the correl-
ation between clinicopathological characteristics and the
let-7d level in RCC (Table 1, Figures 1C and 1D). There
was no significant correlation between let-7d level and
age at surgery or histological subtype. Let-7d level in
RCC was significantly lower in male patients than in
female patients (Table 1), but the difference between
males and females was not found in the adjacent normal
tissues (Additional file 1: Figure S2). Let-7d expression
was significantly lower in T3 stage RCC than in T1 and
T2 stage RCC, and decreased remarkably with advanced
degree of RCC differentiation. Moreover, let-7d expression
in RCC with vascular invasion was significantly lower than
that in RCC without vascular invasion. Therefore, down-
regulation of let-7d is highly correlated with the malignant
degree of RCC.
Let-7d expression is inversely correlated with tumor
macrophage infiltration
We investigated the association between let-7d expression
and changes of several tumor stromal cells including
macrophages, cancer-associated fibroblasts, T-regulatory
cells (Tregs), and mast cells, which have been well docu-
mented to associate with tumor progression [10,21,22].
Figure 1 Let-7d expression in RCC cell line and tumor samples, and correlation with tumor stromal cells. (A) Real-time RT-PCR analysis of
relative let-7d expression in human cell lines. The data represent the average ± SD of three independent RT-PCR results. (B) The relative expression
of let-7d in 80 RCC tissues and matched adjacent normal tissues were analyzed by real-time RT-PCR. (C, D) Real-time RT-PCR analysis of relative
let-7d expression in 80 RCC tissues in different T stages (C) and tumor grades (D). Horizontal lines in (B–D) represent the mean values of relative
let-7d expression for each series of samples. Note that (B–D) were generated from the same data as Table 1. (E) A linear regression and correlation
among relative let-7d expression in a log scale vs. CD68 positive cell counts in five independent fields under × 20 objective lens is shown with r
(Spearman) and P-values indicated.
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mal cells are shown in Additional file 1: Figure S3. Statis-
tics of positive cell counts and their correlation with let-7d
expression level in tumor tissue are shown in Additional
file 2: Table S2. There were no statistically significant links
between let-7d level and counts of cancer associated
fibroblasts, Tregs, and mast cells, but an inverse correl-
ation between let-7d and macrophage number was ob-
served (Spearman’s r = −0.393, P = 0.0003) (Figure 1E).
This suggests a regulatory role of let-7d for macrophage
infiltration in RCC stroma.
Overexpression of let-7d impedes RCC cell growth and
migration of RCC cells in vitro
The low let-7d level in RCC prompted us to investigate
whether let-7d functions as a tumor suppressor in RCC.
We infected the RCC cell lines 786O and 769P with pri-
let-7d lentivirus and measured its effects on cell prolifer-
ation and migration in vitro. After the infection, let-7d
levels in 786O and 769P cells were upregulated (9.6- and
5.3-fold, respectively; Figures 2A and 2B), and their pro-
liferation and migration evaluated by proliferation assay
(Figures 2C and 2D), Boyden chamber assay (Figures 2E
and 2H), and wound-healing assay (Figures 2F, G and I)
were significantly inhibited, as compared with the cellsinfected with the control lentivirus. These results indicate
that let-7d may be a tumor suppressor in RCC.
Overexpression of let-7d decreases the monocyte
recruitment of RCC cells
To investigate the potential mechanism of the inverse
correlation between let-7d expression and tumor macro-
phage infiltration in RCC, we performed chemotaxis as-
says with PBMCs in the upper chamber and conditioned
medium from let-7d-overexpressing 786O or 769P cells
or from control cells in the lower chamber. We found
that overexpression of let-7d in RCC cells led to decreased
migration of PBMCs compared with vehicle control
(Figure 2J). These results suggest the regulatory role of
let-7d in the inhibition of chemotactic activity leading
to the decrease of macrophage infiltration in RCC.
Overexpression of let-7d inhibits the growth, metastasis, and
tumor macrophage infiltration of RCC in animal models
We then used the cell-derived xenograft (CDX) model in
nude mice to investigate the effects of let-7d overexpression
on RCC. The growth of let-7d overexpressing 786O cells
was significantly inhibited and the mean tumor weight
was reduced by 66.4% as compared with the controls
(Figures 3A and 3B). The number of metastatic colonies
Table 1 Relationship between let-7d expression and clinicopathological features in RCC patients
Let-7d expression1 (RQ: 2−ΔCt)
Variable Case no. Median Range P2
Gender 0.036
Male 51 5.7 × 10−3 1.0 × 10−5-1.06
Female 29 0.027 3.1 × 10−5-1.14
Age 0.19
<60(median) 35 7.4 × 10−3 2.1 × 10−5-0.655
≥60 45 8.5 × 10−3 1.0 × 10−5-1.14
T stage <0.0001
T1 and T2 50 0.046 1.9 × 10−4-1.14
T3 30 9.2 × 10−4 1.0 × 10−5-0.067
G grade <0.0001
G1 27 0.28 2.8 × 10−3-1.14
G2 38 5.8 × 10−3 2.1 × 10−5- 0.061
G3 15 2 × 10−4 1.0 × 10−5-6.8 × 10−3
Histological type 0.069
papillary RCC 2 0.026
chromophobe RCC 3 2 × 10−4
clear cell RCC 75 0.011 1 × 10−5-1.14
Vascular invasion 0.010
positive 15 0.0014 1 × 10−5- 0.18
negative 65 0.017 2.1 × 10−5-1.14
1Let-7d expression was normalized to U6.
2Mann–Whitney test for the comparison between two groups or Kruskal-Walis test for more groups.
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specific Alu-sequence (Figure 3E) in the mouse lung
were also significantly reduced. Tumor macrophages as
indicated by CD68+ cells in let-7d overexpressing xeno-
grafts were decreased by 52.7% as compared with the
controls (Figures 3F and 3G).
We further used the patient-derived xenograft model
(PDX), a valuable tool for preclinical trials, in NOD/SCID
mice to evaluate the effect of let-7d overexpression on
RCC growth and metastasis. Early passage (2nd passage)
of the RCC xenografts recapitulated the morphologic fea-
tures of the original clinical tumor (Figure 3H). The let-7d
level in PDX was similar to that in original human RCC
and was significantly decreased as compared with that
in normal adjacent tissues (Figure 3I). By intratumoral
injection of cholesterol-conjugated let-7d mimics [23],
we found that let-7d level in tumors was elevated by
8.6-fold as compared with that in controls (Figure 3I).
Consistent with the results in the CDX model, tumor
growth was suppressed and tumor weight was decreased
after the intratumoral injection of let-7d mimics (Figures 3J
and 3 K). The number of metastatic colonies and the
quantification of human-specific Alu-sequence in mouse
lung were also reduced (Figures 3L–N). The results from
both the CDX and PDX animal models suggest thatoverexpression of let-7d in RCC results in dramatic re-
pression of RCC growth, metastasis, and macrophage in-
filtration, and that administration of let-7d to tumor tissue
may be a therapeutic alternative for RCC.
COL3A1 and CCL7 are direct let-7d target genes in RCC cells
To investigate the mechanism involved in the suppression
effect of let-7d on tumor growth, metastasis, and macro-
phage infiltration in RCC, we first performed in silico
search for the target mRNAs using three algorithms
(MiRanda, PicTar, and TargetScan), and obtained a list
of predicted target mRNAs of let-7d. The genes potentially
involved in tumor growth, metastasis, and chemotaxis
activity of RCC were then selected through data mining
using the Gene Expression Omnibus Database [24]. Pre-
liminary semi-quantitative RT-PCR screening identified
downregulation of COL3A1 and CCL7 mRNA following
forced expression of let-7d (data not shown). Quantitative
real-time RT-PCR, western blot and ELISA confirmed that
the expressions of COL3A1 and CCL7 were significantly
decreased at both mRNA and protein levels in 786O and
769P cells transfected with pri-let-7d (Figures 4B–D). Im-
munohistochemistry staining also showed that COL3A1
and CCL7 were decreased in CDX and PDX samples in
which let-7d was overexpressed (Figure 4E).
Figure 2 Ectopic expression of let-7d in vitro. (A, B) Relative expression of let-7d in pri-let-7d lentivirus-infected cells (786O-let-7d or 769P-let-
7d) compared with vehicle control vector-infected cells (786O-v or 769P-v). (C, D) Cell proliferation was evaluated using CCK-8. (E) Representative
images of migrated cells evaluated by Boyden chamber assay. (a) 786O-v, (b) 786O-let-7d, (c) 769P-v, (d) 769P-let-7d cells. Original magnification:
×100. (F, G) Representative images of wound gaps in let-7d overexpression and control cells at different time points. Original magnification: ×40.
(H, I) The quantification results of migrated cells and percent wound healing are represented as the mean ± SD of three independent
experiments with five random fields counted for each chamber and wound area. (J) PBMC chemotaxis was evaluated by chemotaxis assay.
Results are expressed as mean ± SD of three independent experiments. *P < 0.05.
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targets of let-7d, the 3’-UTRs flanking the putative bind-
ing sites of let-7d in COL3A1 and CCL7 mRNAs were
cloned into reporter plasmids immediately downstream
of luciferase cDNA. The reporter plasmids containing
the mutant putative binding sites of let-7d were also
constructed as the controls (Figure 4A). Luciferase activ-
ities decreased significantly in the cells transfected with
the wild-type reporter plasmids but not in those trans-
fected with the mutant plasmids (Figure 4F). These find-
ings indicate that the 3’-UTRs in COL3A1 and CCL7
mRNAs are the target sites, through which let-7d modu-
lates the expressions of COL3A1 and CCL7.
Rescue of COL3A1 and CCL7 overcomes the effects of let-7d
To confirm that COL3A1 and CCL7 functions down-
stream of let-7d, we performed rescue experiments by
culturing RCC cells in the presence of purified COL3A1
or CCL7. Addition of 0.2 μg/mL COL3A1 restored thegrowth and migration of 786O-let-7d and 769P-let-7d
cells (Figure 5A-C). Addition of 10 ng/mL CCL7 restored
the macrophage recruitment of these two cells (Figure 5D).
However, addition of COL3A1 did not reverse the in-
hibitory effects of let-7d overexpression on macro-
phage recruitment, and CCL7 did not impact growth
and migration of RCC cells (data not shown). These
data demonstrate that let-7d suppresses RCC cell growth,
metastasis, and macrophage recruitment by directly tar-
geting COL3A1 and CCL7.
Inhibition of let-7d in OS-RC-2 cells increased the expression
of COL3A1 and CCL7 and enhanced cell proliferation,
migration, and monocyte recruitment of the cells
To further assess whether let-7d is involved in the prolif-
eration, migration, and tumor macrophage infiltration of
RCC by targeting COL3A1 and CCL7, we inhibited the
expression of let-7d with a synthesized let-7d inhibitor
in a relatively low metastatic OS-RC-2 cell line with high
Figure 3 Overexpression of let-7d in vivo. (A, B) Growth curves and average net weights of xenografts formed by 786O-v (n = 5) and 786O-let-7d
cells (n = 5). (C, D) Representative micrographs and quantitative data of metastatic colonies in mice lung. DiI-positive lung metastatic colonies were
photographed and counted under a laser confocal microscope. (E) Real-time PCR quantification of relative Alu-sequence expression in mice
lung. (F) Quantitative data of the mean CD68 positive cells per five fields in each group. (G) Representative picture of IHC staining of CD68 positive
cells. Original magnification: ×200. Data in (A–F) represent the mean ± SD of five mice per group. P values were obtained by the two-tailed Student’s
t-test. *P < 0.05. (H) HE staining of the patient tumor and its corresponding derived xenograft (2nd passage). Original magnification: ×200. (I) Real-time
RT-PCR analysis of let-7d expression in human RCC tissue, paired normal adjacent tissue, and corresponding PDX tumor tissues 1 week after
intratumoral injection of let-7d mimics or control RNA. (J, K) Growth curves and average net weights of xenografts injected with let-7d
mimics (n = 7), control RNA (n = 7) or PBS control (n = 7). (L, M) Representative pictures and quantitative data of metastatic colonies in mice
lung. (N) Real-time PCR quantification of relative human-specific Alu-sequence expression in mice lung. The values in (J–N) are presented as
the mean ± SD of seven mice. P values were obtained by one-way ANOVA. **P < 0.01 (let-7d mimics vs. PBS or control RNA).
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of endogenous COL3A1 and CCL7 mRNA were increased
by 3.1- and 2.9-fold, respectively, upon let-7d inhibition
compared with the negative control (Figure 6B). Further-
more, western blot and ELISA assay showed that the pro-
tein levels of these two genes were upregulated following
let-7d repression (Figure 6C, D). The inhibition of let-7d
in OS-RC-2 cells significantly increased cell proliferation,migration, and PBMC chemotaxis. Additionally, the
increased chemotaxis was eliminated by the addition of
1 μg/mL CCL7 neutralizing antibody in conditioned
medium (Figure 6E–J). These data further support the
notion that inhibition of let-7d in RCC increases cell
proliferation, migration, and macrophage recruitment
through the modulation of its targets COL3A1 and
CCL7.
Figure 4 Let-7d directly targets COL3A1 and CCL7 in RCC cells. (A) Sequence alignment of human let-7d seed sequence within the
3′-UTRs of COL3A1 and CCL7. The mutated sequence in the putative let-7d binding sites for each gene is shown in the top of each gene set.
(B) Real-time RT-PCR analysis of COL3A1 and CCL7 expression in RCC cells. (C, D) The protein levels of COL3A1 and CCL7 in RCC cells were
detected by western blot and ELISA. Corresponding densitometry of each band is presented in a bar graph. Data presented in (B–D) are the
mean ± SD of three independent experiments. *P < 0.05. (E) IHC staining of COL3A and CCL7 expression in the tumor sections from each
experimental group of PDX and CDX model. Original magnification: ×200. (F) Luciferase activity of various reporter plasmids. Statistical
significance was obtained using one way ANOVA. The data represent the mean ± SD of three independent experiments with triplicates of
each sample.*P < 0.05.
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CCL7 mRNA levels in RCC tissues
We analyzed the relationship between level of let-7d
and the mRNA levels of COL3A1 and CCL7 in clinical
RCC tissues by quantitative real-time RT-PCR Significantinverse correlation was found between let-7d level and
COL3A1 mRNA level in the 80 clinical RCC samples
(Figures 6K and 6 L), and between let-7d level and
CCL7 mRNA level in the clinical RCC samples with T3
stage.
Figure 5 Rescue of COL3A1 and CCL7 in RCC cells. (A) Proliferation assay was performed with or without the addition of 0.2 μg/mL type III
collagen by CCK-8. (B) Representative images of the wound gaps in cells cultured with or without 0.2 μg/mL type III collagen at indicated time
point. Original magnification: ×40. (C) Percent wound healing is shown as the mean ± SD of the three experiments. (D) Migrated PBMC cells were
evaluated by chemotaxis assay with or without 10 ng/mL CCL7. Results are expressed as mean ± SD of three independent experiments. *P < 0.05.
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Let-7d belongs to the let-7 family that functions as tumor
suppressor in many types of cancer [12]. Reported direct
targets of let-7 include oncogenes such as RAS, MYC, and
HMGA2 [25]. In this study, we demonstrated the tumor
suppressive role of let-7d in RCC and validated that the
targets of let-7d were COL3A1, an important stroma com-
ponent, and CCL7, a chemokine attracting monocytes to
tumor tissue. Let-7d expression was negatively correlated
with COL3A1, CCL7 and CD68+ cells in RCC tissues.
Collagen is the most abundant ECM protein in stroma,
and contributes to the tumor progression in tumor stroma
[10]. Elevated deposition of collagen has been particularly
associated with an altered stroma during breast tumori-
genesis and correlated with increased breast cancer risk
[26]. Lysyl oxidase is an ECM crosslinking enzyme. Colla-
gen crosslinking-mediated matrix stiffening increases in-
tegrin clustering, which leads to phosphorylation of focal
adhesion kinase and activation of extracellular signal-
regulated kinase [27]. These changes are all involved in
cell migration, invasion and proliferation, leading to tumor
progression [28]. COL3A1, also known as collagen, typeIII, alpha 1, is a fibrillar collagen found in extensible con-
nective tissues. The increase of COL3A1 and COL1A1 are
found in epithelial ovarian cancers and are prognostic
markers of poor prognosis [29]. Interestingly, COL3A1 is
the target of miR-29 family, and downregulation of this
miRNA family is responsible for the increased invasive-
ness of lung cancer [30,31]. Here, we validated through
in vitro and in vivo research that COL3A1 is a functional
direct target gene of let-7d. Importantly, COL3A1 expres-
sion was inversely correlated with let-7d levels in RCC
clinical specimens. Our findings suggest the involvement
of the let-7d-COL3A1 regulatory pathway in RCC growth
and metastasis.
Macrophages, which are abundant in the tumor micro-
environment, were proven to promote cancer initiation
and malignant progression by persuasive clinical and ex-
perimental evidence [32]. Tumor-associated macrophages
are also involved in tumor progression of RCC and can be
used as a potential therapeutic target for metastatic RCC
[33]. CCL7 (monocyte chemotactic protein-3, MCP-3) is a
member of the C-C chemokine subfamily. CCL7 has been
found to be overexpressed in gastric cancer tissues and is
Figure 6 Inhibition of let-7d in OS-RC-2 cells. (A, B) Real-time RT-PCR quantification of relative expression of let-7d (A), COL3A1 and CCL7 (B)
in let-7d inhibitor or negative control transfected OS-RC-2 cells. (C) Western blot and (D) ELISA of COL3A1 and CCL7 expression. Corresponding
densitometry of each band is presented in a bar graph. Data presented are the mean ± SD of three independent experiments. (E) Proliferation assay
was performed by CCK-8. (F, G) Representative images and quantitative data of migrated negative control- (a) or let-7d inhibitor- (b) transfected
OS-RC-2 cells evaluated by Boyden chamber assay. Original magnification: ×100. (H) Representative images of wound gaps in let-7d inhibitor- and
control-transfected OS-RC-2 cells at different time points. Original magnification: ×40. (I) The quantification results of percent wound healing are
represented as the mean ± SD of three independent experiments. (J) PBMC chemotaxis was evaluated by chemotaxis assay with the presence of
1 μg/mL CCL7 neutralizing antibody or control IgG in the conditioned medium. Results are expressed as mean ± SD of three independent
experiments. *P < 0.05. (K, L) The linear regression and correlation between let-7d and COL3A1 mRNA levels in all 80 RCC tissues (K) and
between let-7d and CCL7 mRNA levels in all 30 T3 stage RCC tissues from the same set (L). Expression status is shown as the tumor/non-tumor
ratio in a log scale.
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prognosis [34]. Furthermore, CCL7 is more abundant in
metastatic tumor site than in the primary site, and is asso-
ciated with macrophage infiltration in tumor [35]. For
example, CCL7 is higher in brain metastatic RCC than in
primary RCC [36]. CCL2 is another potent macrophage
chemoattractant chemokine belonging to the same che-
mokine family with CCL7. CCL2 recruits macrophages
to facilitate metastasis of breast cancer [37]. In RCC
[38], however, CCL2 was shown to be of minor import-
ance in the recruitment of macrophages that preserve
diverse tumor-promoting functions. CCL7 promotes the
invasion and migration of oral squamous cell carcinoma
cells through directly binding to its receptor [39]. Inter-
estingly, we found that the suppressed proliferation and
migration in let-7d overexpressing RCC cells could notbe restored by the addition of exogenous CCL7 alone,
probably due to the multiple pathways downstream of
let-7d or the lack of functional CCL7 receptor in RCC
cells. However, a strong inverse correlation between let-7d
expression and number of infiltrated macrophage was
found in our clinical RCC samples. Therefore, there is an
indirect role of CCL7 in RCC malignancy via the let-
7d-CCL7-macrophage chain. The negative correlation
between let-7d expression and CCL7 in T3 stage RCC
tissues additionally highlights the role of CCL7 in tumor
invasion and metastasis. CCL7 may be functionally in-
volved in RCC malignant progression and may be used in
chemokine target therapy for RCC.
In summary, our results indicate that the tumor sup-
pression role of let-7d in RCC may be partially ascribed to
its ability to decrease collagen expression and macrophage
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mRNAs. If sufficient let-7d is present in RCC, tumor
stroma will be remodeled and cancer cells will be sup-
pressed. It should be noted that let-7d may possess
various functions owing to its pleiotropic regulation of
genes. It is our expectation that more functional let-7d
target genes will be identified in the near future. Further
studies are required to fully illustrate their functional roles
and interactions with tumor-associated stroma and to de-
termine whether let-7d can be used for the therapy of
metastatic RCC, as described in other cancers [23].
Conclusions
This study demonstrated that let-7d may suppress RCC
growth, metastasis and tumor macrophage infiltration at
least partially through targeting COL3A1 and CCL7.
Our findings suggest let-7d as a promising target for
metastatic RCC therapies.
Methods
Clinical samples and cell lines
A total of 80 paired RCC tissues and adjacent normal tis-
sues were obtained with informed consent from patients
who underwent surgical resection at Peking University First
Hospital between 2012 and 2013. The study was approved
by Review Board of Peking University First Hospital. All
histological subtypes were classified by the Heidelberg clas-
sification [40]. Pathological T stage was classified according
to the 2010 TNM classification system [41]. Tumor grade
was assessed according to Fuhrman nuclear grade [42]. The
presence of vascular invasion includes either microvascular
invasion, renal vein invasion or inferior vena cava invasion.
Immortalized renal proximal tubule epithelial cell line of
HK-2 and human RCC cell lines of A498, 769P, 786O,
Caki-1 and Caki-2 were purchased from ATCC (MA,
USA). Human RCC cell line OS-RC-2 was obtained from
the cell bank at Chinese academy of sciences. Transformed
human embryonic kidney cells 293FT were purchased from
Invitrogen. A498, 769P, 786O, and OS-RC-2 cells were
maintained in RPMI 1640 medium, HK-2, Caki-1 and
Caki-2 cells in DMEM/F12 (50:50, v/v) medium, and
293FT cells in DMEM. These media were supplemented
with 10% fetal bovine serum (HyClone), and penicillin
(100 U/mL)/streptomycin (100 μg/mL) (Invitrogen).
Peripheral blood mononuclear cell (PBMC) isolation
Heparinized venous blood obtained from RCC patients
with informed consent was diluted 1:5 with phosphate
buffer saline (PBS) and the 40 mL diluted blood was
then underlaid on 10 mL of Ficoll (Seromed, Berlin,
Germany) in 50 mL plastic tube. After centrifugation at
400 × g for 20 minutes, PBMC were aspirated from the
interface, washed with PBS and resuspended to 4 × 106
cells/mL in complete RPMI 1640 medium [43].In vivo assay
All mice were maintained in accordance with the NIH
Guidelines for the Care and Use of Laboratory Animals
with the approval of Review Board of Peking University
First Hospital, Beijing. Patient derived xenograft (PDX)
model was established as previously described [23]. RCC
surgical samples were gently grinded, labeled with Cell
Tracker™ CM-Dil dye (MoBiTec, Göttingen, Germany)
and subcutaneously injected into NOD/SCID mice
(Vitalriver, Beijing, China). The xenograft was then
harvested, minced into pieces and transplanted into
successive mice. For establishment of RCC cell derived
xenograft (CDX) model, 5-week old female BALB/C
nude mice (Chinese Academy of Sciences, Shanghai,
China) were subcutaneously inoculated with 786-O cells
labeled with Dil dye and stably transfected with 3 × 106
pri-let-7d or vehicle control lentivirus. Growth of estab-
lished xenografts was monitored every two days by a
caliper for length (L) and width (W) measurement. Tumor
volumes were calculated using the formula (L × W2) / 2.
In vivo treatment of miRNA mimics in PDX model was
performed as previously described [23]. 20 nM chemically-
modified mi-Ribo™ hsa-let-7d mimics or mi-Ribo™ hsa-let-
7d control (Ribobio Co., Guangzhou, China) in 50 μL PBS
mixed with 50 μL in vivo transfection reagent Entran-
ster™-in vivo (Engreen, Beijing, China) were locally
injected into the tumor mass once every 3 days for 3
weeks. Quantification of the RCC cell lung metastatic
colonies were obtained by examining the mice lung
using the TCS 4D laser scanning confocal microscope
(Leica, Heidelberg, Germany).
RNA extraction and real-time RT-PCR
Total RNA was extracted using miRNeasy Mini Kit
(Qiagen, Hilden, Germany). For miRNA quantification,
100 ng total RNA was either reverse transcribed directly
using stem-loop primers [44], or was polyadenylated
with polyA polymerase (NEB, Beverly, MA, USA) then
reverse-transcribed with an oligo-dT adapter primer into
cDNAs for quantitative real-time PCR [45]. Although
both reverse-transcription methods yield reliable and
comparative results, the polyA polymerase tailing method
was used in this experiments unless specified, given that it
allows measuring multiple target miRNAs with one RT
reaction. For mRNA analyses, cDNAs were synthesized
from 2 μg total RNA, using oligo(dT)15 primers and
Moloney murine leukemia virus reverse transcriptase
(Invitrogen). Quantitative real-time PCR was performed
using the SYBR Green PCR Master Mix (Toyobo, Osaka,
Japan) in a final volume of 10 μL in ABI 7500 Fast PCR
machine. The expression of miRNA and mRNAs were
normalized to U6 and GAPDH, respectively. Data are
presented as relative quantification (RQ) based on the
calculation of 2−ΔCt. ΔCt was derived from subtracting
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cDNA of interest. (For a list of all the primers, see Sup-
porting Data, Additional file 2: Table S1)Lentiviral transduction
The human pri-let-7d (primary transcript of let-7d) cDNA
sequence was synthesized and inserted into the lentiviral
shuttle vector plenti6 (Invitrogen) to generate human
plenti6-pri-let-7d plasmid. Plenti6 control and human
pri-let-7d lentivirus were generated by transfecting 3 μg
of plenti6 or plenti6- pri-let-7d and 9 μg of ViraPower
Packaging Mix (Invitrogen) into 293FT packaging cells
using Lipofectamine 2000. After overnight exposure to
the transfection mixture, the medium was changed, and
the virus-containing supernatant was harvested 48 h
later. The infected cells were selected with 5 μg/mL
blasticidin. The antibiotic-resistant clones were pooled
and used for subsequent assays.In vitro cell proliferation, migration, wound healing, and
chemotaxis assays
The cell proliferation assay was performed by using Cell
Counting Kit-8 (CCK-8, Dojindo, Kumamoto, Japan). Cell
migration was evaluated by Boyden chamber assay and
wound healing assay [46]. Monocyte chemotaxis was
assayed in 24-well transwell plates (Costar #3421) with
5 μm pore polycarbonate filter membrane. Briefly, 1 × 107
RCC cells were cultured in 5 mL complete medium for
24 h, the cultured media were collected after centrifuga-
tion and used as conditioned media. PBMC were resus-
pended in 0.1% BSA-RPMI medium, 4 × 105 cells in
100 μL medium were added to the upper chamber of
the 24-transwell apparatus, and 800 μL conditioned
medium were added in the lower chamber. After incu-
bation for 8 h, cells that migrated though the membrane
were fixed with100% methanol, stained by Giemsa dye,
and counted under a microscope. Five high-power fields
(×200) were randomly selected and manually counted
for each well. The experiment was performed in triplicate
(3 wells) with three independent tests. Human recombin-
ant COL3A1 (Fitzgerald, Sudbury, MA) (0.2 μg/mL),
human recombinant CCL7 (PeproTech, Rocky Hill, NJ)
(10 ng/mL), CCL7 neutralizing antibody and normal goat
IgG control antibody (R&D Systems, Minneapolis, MN)
(1 μg/mL) were used in these assays.Elisa
Cultured media of RCC cells were used for detection
of CCL7 by CCL7 ELISA kits (Ray Biotech, Inc). The
optical density (OD) at 450 nm was quantified with a
Multiskan microplate spectrophotometer (Thermo Lab-
Systems, Milford, MA).Quantitative detection of human tumor cell metastasis
The detection of RCC metastasis in mice lung was per-
formed as described previously [47]. Genomic DNA was
extracted from mouse lung tissues using the EasyPure
Genomic DNA Kit (Transgen Biotech, Beijing, China).
Quantitative real-time PCR was used to measure human
Alu-sequences specific for the most conserved region of
humans. The primers for Alu-sequences and PCR condi-
tions were used as previously described [47]. The level of
human Alu-sequence was normalized to the amount of
mouse/human GAPDH genomic DNA sequence ampli-
fied by using mouse/human GAPDH primers [48].
Immunohistochemistry (IHC) and toluidine blue staining
Paraffin embedded tissues were analyzed using immuno-
histochemical staining [49] with the following primary
antibodies: anti-CD68 antibody (DAKO, Carpinteria, CA),
anti-α-SMA antibody (DAKO, Carpinteria, CA), anti-CCL7
antibody (Gen Way Biotech, San Diego, CA), anti-COL3A1
antibody (Bioss, Beijing, China), anti-FOXP3 antibody
(Biolegend, San Diego, CA) and rabbit anti-Mouse CD68
antibody (Bioss, Beijing, China). For quantification of
tumor stromal cells within the tumor area, CD68 was
used as a pan-macrophage marker, α-SMA was used to
detect cancer activated fibroblasts adjacent to RCC cells
[50], FOXP3 was used as a specific marker for regula-
tory T cells (Tregs) [22], and mast cells were assessed
using the routine toluidine blue staining method [21].
Each tumor section was evaluated by using 20× objective
lens, and five independent areas with the most abundant
positive cells were selected, digitally photographed, and
manually counted under a microscope. The average posi-
tive cell counts for each patient were used for statistical
analysis. For quantification of CD68+ cells in CDX xeno-
grafts, four sections from each xenograft were randomly
selected and quantified as described above, the average
positive cells for each mouse were used for statistical ana-
lysis. Results were confirmed by two pathologists in a
double-blind analysis.
Western blot analysis
The lysates were obtained by lysing cells in lysis buffer
containing 50 mM Tris, pH7.4, 150 mM NaCl, 0.25%
sodium deoxycholate, 1% NP-40, 0.1% SDS, 1 mM
PMSF, and complete protease inhibitor cocktail (Roche,
Mannheim, Germany). Equal amounts of total protein
were subjected to 10% SDS-PAGE and blotted onto PVDF
membranes (Pall, Pensacola, FL). Western blotting was
performed using rabbit anti-human COL3A1 antibody
(Bioss, Beijing, China). The blotting membranes were
scanned using GeneSnap acquisition software (Syngene,
Cambridge, UK) and band densities were quantified with
the GeneTool program (Syngene, Synoptics). GAPDH
were used as internal control.
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The 3′-UTR of human COL3A1 and CCL7 containing
the putative binding sites and the mutant binding sites
of the mature hsa-let-7d were chemically synthesized
and inserted immediately downstream of the luciferase
cDNA in the pGL3-control vector (Promega, Madison, WI)
by GenePharma (Shanghai, China) to form pGL3-COL3A1,
pGL3-CCL7 and pGL3-COL3A1-Mut, pGL3-CCL7-Mut
constructs. Twenty-four hours before transfection, 786O
and 293FT cells were plated at 1.5 × 105 cells/well in
24-well plates. 0.5 μg of pGL3 constructs plus 0.08 μg
of pRL-TK (Promega) were transfected in combination
with 60 pmol of either a stability-enhanced nontarget-
ing RNA control oligonucleotide or stability-enhanced
hsa-let-7d oligonucleotides (GenePharma, Shanghai, China)
using Lipofectamine 2000 (Invitrogen). After 48 h, lucif-
erase activity was measured using the Dual Luciferase
Reporter Assay System (Promega). Firefly luciferase ac-
tivity was normalized to renilla luciferase activity for
each transfected well. The results were obtained from three
independent experiments and each one was performed in
triplicate.Inhibition of let-7d with a miRNA inhibitor
The chemically-modified mi-Ribo™ hsa-let-7d inhibitor
or mi-Ribo™ hsa-let-7d negative control oligonucleotides
were synthesized by Ribobio Co. (Guangzhou, China). RCC
cells were transfected using Lipofectamine 2000. Cells were
collected and assayed at 72 h post-transfection.Statistical analysis
Data are presented as mean ± SD and were analyzed
using the statistical package SPSS17.0 or GraphPad
Prism software 5.0. The significance of differences be-
tween two groups was determined using a two-sided
Student’s t-test. In case of multiple tests, one-way
ANOVA followed by Bonferroni-Holm procedure was
applied. Correlation was performed using two-tailed
Spearman’s test. P ≤ 0.05 was considered statistically
significant.Additional files
Additional file 1: Figure S1. SYBR green real-time RT-PCR analysis
shows that there is no significant difference in let-7a expression level
between RCC tissue and paired adjacent normal tissue. Horizontal lines
represent the relative mean values of let-7a expression for each series of
samples. Figure S2. SYBR green real-time RT-PCR analysis demonstrates
that there is no significant difference in let-7d expression level in adjacent
normal tissues between male and female patients. Horizontal lines represent
the relative mean values of let-7d expression for each series of samples.
Figure S3. Representative pictures of positive stromal cells (arrow) in RCC.
(Original magnification: ×200). (a) CD68+ macrophages. (b) α-SMA positive
cancer associated fibroblasts. (c) Toluidine blue metachromatic mast cells.
(d) FOXP3+ T-regulatory cells.Additional file 2: Table S1. Primer sequences. Table S2. Statistics of
positive cell counts and their correlation with let-7d expression level in
tumor tissue.
Abbreviations
RCC: Renal cell carcinoma; PDX: Patient derived xenograft; CDX: Cell derived
xenograft; Dil: 1,1-dioctadecyl-3,3,3’,3’-tetramethyl-indocarbocyanine
perchlorate; RT-PCR: Reverse transcription-polymerase chain reaction;
RQ: Relative quantification; ECM: Extracellular matrix.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
B.Su, B.Shi, Z.Z, Y.X., F.X., Z.G., X.L., W.Z., Z.Q.Z. and L.Z. conceived the
experiments and analysed the data; Q. S. and J. W. examined the tumor
sections. B.Su, W.Z., B.Shi, Z.Z, Y.X., F.X., X.Z., J.L. and Z.G. carried out experiments;
B.Su and Y.X. drafted the manuscript. Z.Q.Z. and L.Z. supervised research project,
acted as corresponding authors and did the revisions. All authors were involved
in writing the paper and approved the submitted manuscript.
Acknowledgments
This study was supported by grants from the Beijing Natural Science
Foundation (No.7122183) and the National Natural Science Foundation
(Grant No.81372746).
Author details
1Department of Urology, Peking University First Hospital & the Institute of
Urology, Peking University, Beijing 100034, China. 2National Urological Cancer
Center, Beijing 100034, China. 3Department of Cell Biology, Peking University
School of Oncology, Beijing Cancer Hospital and Institute, Beijing 100142,
China. 4Department of Urology, Peking University Shenzhen Hospital,
Shenzhen, Guangdong 518036, China. 5Department of Urological pathology,
Peking University First Hospital & the Institute of Urology, Peking University,
Beijing 100034, China.
Received: 25 April 2014 Accepted: 26 August 2014
Published: 6 September 2014
References
1. Ramana J: RCDB: Renal Cancer Gene Database. BMC Res Notes 2012, 5:246.
2. Curti BD: Renal cell carcinoma. JAMA 2004, 292:97–100.
3. Vogelzang NJ, Stadler WM: Kidney cancer. Lancet 1998, 352:1691–1696.
4. Rini BI, Campbell SC, Escudier B: Renal cell carcinoma. Lancet 2009,
373:1119–1132.
5. Motzer RJ, Russo P, Nanus DM, Berg WJ: Renal cell carcinoma. Curr Probl
Cancer 1997, 21:185–232.
6. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC,
Caton JJ, Munshi N, Crawford ED: Nephrectomy followed by interferon
alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell
cancer. N Engl J Med 2001, 345:1655–1659.
7. Croce CM, Calin GA: miRNAs, cancer, and stem cell division. Cell 2005,
122:6–7.
8. Cui SY, Huang JY, Chen YT, Song HZ, Feng B, Huang GC, Wang R, Chen LB,
De W: Let-7c governs the acquisition of chemo- or radioresistance and
epithelial-to-mesenchymal transition phenotypes in docetaxel-resistant
lung adenocarcinoma. Mol Cancer Res 2013, 11:699–713.
9. Joyce JA, Pollard JW: Microenvironmental regulation of metastasis.
Nat Rev Cancer 2009, 9:239–252.
10. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation.
Cell 2011, 144:646–674.
11. Soon P, Kiaris H: MicroRNAs in the tumour microenvironment: big role for
small players. Endocr Relat Cancer 2013, 20:R257–R267.
12. Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME: The role of let-7 in
cell differentiation and cancer. Endocr Relat Cancer 2010, 17:F19–F36.
13. Bussing I, Slack FJ, Grosshans H: let-7 microRNAs in development, stem
cells and cancer. Trends Mol Med 2008, 14:400–409.
14. Thomson JM, Parker J, Perou CM, Hammond SM: A custom microarray
platform for analysis of microRNA gene expression. Nat Methods 2004,
1:47–53.
Su et al. Molecular Cancer 2014, 13:206 Page 13 of 13
http://www.molecular-cancer.com/content/13/1/20615. Shimizu S, Takehara T, Hikita H, Kodama T, Miyagi T, Hosui A, Tatsumi T,
Ishida H, Noda T, Nagano H, Doki Y, Mori M, Hayashi N: The let-7 family of
microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced
apoptosis in human hepatocellular carcinoma. J Hepatol 2010,
52:698–704.
16. Zhao B, Han H, Chen J, Zhang Z, Li S, Fang F, Zheng Q, Ma Y, Zhang J, Wu
N, Yang Y: MicroRNA let-7c inhibits migration and invasion of human
non-small cell lung cancer by targeting ITGB3 and MAP4K3. Cancer Lett
2014, 342:43–51.
17. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F,
Lieberman J, Song E: let-7 regulates self renewal and tumorigenicity of
breast cancer cells. Cell 2007, 131:1109–1123.
18. Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA, Feig C,
Lengyel E, Peter ME: Let-7 expression defines two differentiation stages
of cancer. Proc Natl Acad Sci U S A 2007, 104:11400–11405.
19. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier
E, Reinert KL, Brown D, Slack FJ: RAS is regulated by the let-7 microRNA
family. Cell 2005, 120:635–647.
20. Liu Y, Yin B, Zhang C, Zhou L, Fan J: Hsa-let-7a functions as a tumor
suppressor in renal cell carcinoma cell lines by targeting c-myc. Biochem
Biophys Res Commun 2012, 417:371–375.
21. Tuna B, Yorukoglu K, Unlu M, Mungan MU, Kirkali Z: Association of mast cells
with microvessel density in renal cell carcinomas. Eur Urol 2006, 50:530–534.
22. Liotta F, Gacci M, Frosali F, Querci V, Vittori G, Lapini A, Santarlasci V, Serni S,
Cosmi L, Maggi L, Angeli R, Mazzinghi B, Romagnani P, Maggi E, Carini M,
Romagnani S, Annunziato F: Frequency of regulatory T cells in peripheral
blood and in tumour-infiltrating lymphocytes correlates with poor
prognosis in renal cell carcinoma. BJU Int 2011, 107:1500–1506.
23. Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, Qin L, Wu X, Zheng Y, Yang
Y, Tian W, Zhang Q, Wang C, Zhang Q, Zhuang SM, Zheng L, Liang A, Tao
W, Cao X: Identification of miRNomes in human liver and hepatocellular
carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular
carcinoma. Cancer Cell 2011, 19:232–243.
24. Gene Expression Omnibus Database. [http://www.ncbi.nlm.nih.gov/geoprofiles/]
25. Roush S, Slack FJ: The let-7 family of microRNAs. Trends Cell Biol 2008,
18:505–516.
26. Provenzano PP, Eliceiri KW, Campbell JM, Inman DR, White JG, Keely PJ:
Collagen reorganization at the tumor-stromal interface facilitates local
invasion. BMC Med 2006, 4:38.
27. Ng MR, Brugge JS: A stiff blow from the stroma: collagen crosslinking
drives tumor progression. Cancer Cell 2009, 16:455–457.
28. Provenzano PP, Inman DR, Eliceiri KW, Keely PJ: Matrix density-induced
mechanoregulation of breast cell phenotype, signaling and gene
expression through a FAK-ERK linkage. Oncogene 2009, 28:4326–4343.
29. Santala M, Simojoki M, Risteli J, Risteli L, Kauppila A: Type I and III collagen
metabolites as predictors of clinical outcome in epithelial ovarian
cancer. Clin Cancer Res 1999, 5:4091–4096.
30. Maurer B, Stanczyk J, Jungel A, Akhmetshina A, Trenkmann M, Brock M,
Kowal-Bielecka O, Gay RE, Michel BA, Distler JH, Gay S, Distler O:
MicroRNA-29, a key regulator of collagen expression in systemic
sclerosis. Arthritis Rheum 2010, 62:1733–1743.
31. Rothschild SI, Tschan MP, Federzoni EA, Jaggi R, Fey MF, Gugger M,
Gautschi O: MicroRNA-29b is involved in the Src-ID1 signaling pathway
and is dysregulated in human lung adenocarcinoma. Oncogene 2012,
31:4221–4232.
32. Qian BZ, Pollard JW: Macrophage diversity enhances tumor progression
and metastasis. Cell 2010, 141:39–51.
33. Santoni M, Massari F, Amantini C, Nabissi M, Maines F, Burattini L, Berardi R,
Santoni G, Montironi R, Tortora G, Cascinu S: Emerging role of tumor-associated
macrophages as therapeutic targets in patients with metastatic renal cell
carcinoma. Cancer Immunol Immunother 2013, 62:1757–1768.
34. Hwang TL, Lee LY, Wang CC, Liang Y, Huang SF, Wu CM: CCL7 and CCL21
overexpression in gastric cancer is associated with lymph node
metastasis and poor prognosis. World J Gastroenterol 2012, 18:1249–1256.
35. Okada M, Saio M, Kito Y, Ohe N, Yano H, Yoshimura S, Iwama T, Takami T:
Tumor-associated macrophage/microglia infiltration in human gliomas is
correlated with MCP-3, but not MCP-1. Int J Oncol 2009, 34:1621–1627.
36. Wyler L, Napoli CU, Ingold B, Sulser T, Heikenwalder M, Schraml P, Moch H:
Brain metastasis in renal cancer patients: metastatic pattern,
tumour-associated macrophages and chemokine/chemoreceptor
expression. Br J Cancer 2014, 110:686–694.37. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder
LA, Pollard JW: CCL2 recruits inflammatory monocytes to facilitate
breast-tumour metastasis. Nature 2011, 475:222–225.
38. Hemmerlein B, Johanns U, Kugler A, Reffelmann M, Radzun HJ:
Quantification and in situ localization of MCP-1 mRNA and its relation to
the immune response of renal cell carcinoma. Cytokine 2001, 13:227–233.
39. Jung DW, Che ZM, Kim J, Kim K, Kim KY, Williams D, Kim J: Tumor-stromal
crosstalk in invasion of oral squamous cell carcinoma: a pivotal role of
CCL7. Int J Cancer 2010, 127:332–344.
40. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN,
Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G,
Schmidt D, Srigley JR, Störkel S, van den Berg E, Zbar B: The Heidelberg
classification of renal cell tumours. J Pathol 1997, 183:131–133.
41. Pichler M, Hutterer GC, Chromecki TF, Jesche J, Kampel-Kettner K, Groselj-Strele
A, Hoefler G, Pummer K, Zigeuner R: Comparison of the 2002 and TNM
classification systems regarding outcome prediction in clear cell and
papillary renal cell carcinoma. Histopathology 2010, 2013(62):237–246.
42. Fuhrman SA, Lasky LC, Limas C: Prognostic significance of morphologic
parameters in renal cell carcinoma. Am J Surg Pathol 1982, 6:655–663.
43. Sica A, Saccani A, Bottazzi B, Bernasconi S, Allavena P, Gaetano B, Fei F,
LaRosa G, Scotton C, Balkwill F, Mantovani A: Defective expression of the
monocyte chemotactic protein-1 receptor CCR2 in macrophages associated
with human ovarian carcinoma. J Immunol 2000, 164:733–738.
44. Varkonyi-Gasic E, Hellens RP: Quantitative stem-loop RT-PCR for detection
of microRNAs. Methods Mol Biol 2011, 744:145–157.
45. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu
NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ, Guegler KJ: Real-time
quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005,
33:e179.
46. Lan L, Han H, Zuo H, Chen Z, Du Y, Zhao W, Gu J, Zhang Z: Upregulation
of myosin Va by Snail is involved in cancer cell migration and
metastasis. Int J Cancer 2010, 126:53–64.
47. Zijlstra A, Mellor R, Panzarella G, Aimes RT, Hooper JD, Marchenko ND,
Quigley JP: A quantitative analysis of rate-limiting steps in the metastatic
cascade using human-specific real-time polymerase chain reaction.
Cancer Res 2002, 62:7083–7092.
48. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun-Prieto L,
Delafontaine P, Prockop DJ: Intravenous hMSCs improve myocardial
infarction in mice because cells embolized in lung are activated to
secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009, 5:54–63.
49. He L, Ding H, Wang JH, Zhou Y, Li L, Yu YH, Huang L, Jia WH, Zeng M, Yun
JP, Luo RZ, Zheng M: Overexpression of karyopherin 2 in human ovarian
malignant germ cell tumor correlates with poor prognosis. PLoS One
2012, 7:e42992.
50. Yao Q, Cao S, Li C, Mengesha A, Kong B, Wei M: Micro-RNA-21 regulates
TGF-beta-induced myofibroblast differentiation by targeting PDCD4 in
tumor-stroma interaction. Int J Cancer 2011, 128:1783–1792.
doi:10.1186/1476-4598-13-206
Cite this article as: Su et al.: Let-7d suppresses growth, metastasis, and
tumor macrophage infiltration in renal cell carcinoma by targeting
COL3A1 and CCL7. Molecular Cancer 2014 13:206.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
